Cite
HARVARD Citation
Cortes, J. et al. (2016). Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet. 3 (12), pp. e581-e591. [Online].